RecruitingNot applicableNCT06251115

Clinical Study on the Safety and Efficacy of QY-1-T in the Treatment of HBV-associated Advanced HCC

Studying Fibrolamellar hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Principal Investigator
Jiang Long, MD, MD
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Intervention
QY-1-T(drug)
Enrollment
9 enrolled
Eligibility
18-75 years · All sexes
Timeline
20242025

Study locations (1)

Collaborators

Shenzhen Zhongke Qiyuan Biotechnology Co., Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06251115 on ClinicalTrials.gov

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Fibrolamellar hepatocellular carcinoma

← Back to all trials